Harnessing viral
power: immunotherapy's synergy with targeted oncolytic viruses
Mohammad Shenagari 1*, Hanieh
Mohammadi-Pilehdarboni 2
1 Department
of Microbiology, School of Medicine, Guilan University of Medical Sciences,
Rasht, Iran
2 Queen
Mary University of London, London, United Kingdom
Corresponding Authors: Mohammad
Shenagari
* Email: Shenagari@gmail.com
Abstract
Cancer treatment has witnessed a profound transformation in recent
decades, with combination therapy emerging as a beacon of hope for patients.
This review delves into the groundbreaking synergy between immunotherapy and
targeted oncolytic viruses, offering a glimpse into the future of cancer
conquering. Traditional methods like surgery, radiation, and chemotherapy have
limitations, especially in advanced or metastatic cancers. Immunotherapy,
inspired by the body's innate defenses, leverages the immune system to
selectively identify and eradicate cancer cells. Immune checkpoint inhibitors,
such as pembrolizumab and nivolumab, have showcased remarkable success in
clinical trials, unlocking the potential of the immune system against once-intractable
cancers. In tandem, oncolytic viruses exhibit precision targeting, minimizing
harm to healthy tissues. Notably, herpes simplex virus type 1 (HSV-1) has
proven effective against various malignancies. The fusion of immunotherapy and
oncolytic viruses represents a paradigm shift in cancer treatment, harnessing
the strengths of each modality. This review explores mechanisms, recent
developments, clinical triumphs, and the challenges of combination therapy. The
dynamic synergy of these two approaches promises to revolutionize cancer
treatment, transforming it from an insurmountable foe into a manageable
condition.
Keywords: Immunotherapy, Oncolytic viruses, Combination therapy, Immune
checkpoint inhibitors, Cancer treatment
Introduction
Cancer, the relentless scourge of our time, continues
to cast its long shadow over the lives of millions worldwide. The global burden
of this insidious disease is staggering, with an estimated 19.3 million new
cancer cases and 10 million cancer-related deaths reported in 2020 alone (1).
These harrowing statistics underscore the pressing need for modern, innovative,
and effective cancer treatment methods that can provide a glimmer of hope
amidst the daunting challenges posed by this complex ailment. Cancer, a
heterogeneous group of diseases characterized by the uncontrolled growth and
spread of abnormal cells, defies easy categorization (2). It infiltrates
virtually every organ system, from the blood to the bone, and carries with it a
diverse array of subtypes and mutations that further complicate diagnosis and
treatment. In the face of this formidable adversary, the oncology community has
relentlessly pursued novel strategies to combat cancer's relentless advance.
Traditionally, cancer treatment has relied on a triad
of approaches: surgery, radiation therapy, and chemotherapy (3). While these
modalities have been instrumental in extending the lives of countless cancer
patients, they come with their own set of limitations. Surgery is often
restricted to early-stage tumors, while radiation therapy can cause collateral
damage to healthy tissues. Chemotherapy, although a mainstay of cancer
treatment, often elicits severe side effects, leading to a diminished quality of
life for patients. The epidemiological landscape of cancer further complicates
the quest for effective treatments. Age, genetics, lifestyle factors, and
environmental exposures all play pivotal roles in determining an individual's
susceptibility to cancer (2). Moreover, the rise of cancer incidence in low-
and middle-income countries adds a layer of complexity, as disparities in
access to healthcare and treatment options persist (4). In the midst of these
formidable challenges, a ray of hope has emerged on the horizon in the form of
immunotherapy and oncolytic virotherapy (5). These groundbreaking approaches
have heralded a paradigm shift in the field of oncology, offering a glimmer of
optimism in the relentless battle against cancer.
I. Cancer immunotherapy
In the realm of cancer treatment, immunotherapy has
emerged as a revolutionary approach, transforming the oncology landscape and
providing renewed hope to patients with various malignancies. Notable recent
developments in immunotherapy have propelled the field forward, paving the way
for enhanced therapeutic strategies and improved patient outcomes (6).
I.a. Monoclonal Antibodies (mAbs)
Monoclonal antibodies (mAbs) have revolutionized
cancer treatment through their precise targeting mechanisms. These
immunoglobulins possess two Fab terminals for direct target binding and an Fc
terminal for interactions with immune cell receptors, modulating their modes of
action (MOA) (7). Notably, Fc-mediated effector functions encompass
complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated
cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) (8).
CDC involves Fc interaction with complement component C1q, initiating immune
responses. ADCC and ADCP operate via direct Fc-FcyR interactions, engaging NK
cells and macrophages, respectively, in tumor cell elimination.
mAbs can also bind and block soluble antigens and
disease-related mediators. FDA-approved mAbs, such as rituximab and
trastuzumab, have transformed the treatment landscape. Antibody drug conjugates
(ADCs) exhibit direct cytotoxicity by delivering payloads to target cells.
While hematological tumors are more accessible to mAbs due to their
microenvironment, ADCs are increasingly promising in treating solid tumors.
Fc-engineering enhances mAbs' antitumor and immune activation activities. For
example, Tafasitamab, targeting CD-19, underwent Fc-related modifications,
resulting in impressive clinical outcomes (9).
Despite mAbs' advantages, cytokine storms can induce
severe side effects in some patients. Reducing immunogenicity through
Fe-engineering may enhance safety. While mAbs are administered via injection,
nanobodies, lacking an Fe terminal, offer higher tissue permeability and lower
production costs. Combinations with chemotherapy and targeted therapies are
common, emphasizing mAbs' enduring importance (10).
I.b. Bispecific Monoclonal Antibodies (bsAbs)
Bispecific mAbs (bsAbs) offer enhanced antitumor
effects by simultaneously binding multiple targets. They provide better
stability, specificity, and fewer side effects. Blinatumomab, targeting CD19
and CD3, has achieved high response rates in clinical trials (11). Several
bsAbs targeting diverse antigens are in development, including MEDl5752, which
targets PD-1 and CTLA-4. Manufacturing challenges and optimal dosing strategies
remain for bsAbs, especially in solid tumors. However, clinical studies are ongoing,
with promising results. As more bsAbs enter the market, their potential in
cancer therapy is expected to grow (12).
I.c. Immune Checkpoint Monoclonal Antibodies
Immune checkpoint mAbs target regulatory molecules
like CTLA-4 and PD-1 on T cells, unleashing the immune system's antitumor
potential. These therapies have revolutionized cancer treatment. CTLA-4
inhibition with ipilimumab has improved melanoma survival. PD-1/PD-L1 mAbs like
pembrolizumab have shown remarkable results across various cancers, especially
when combined with chemotherapy or targeted therapy (13). Fe-engineering
strategies enhance the MOA of immune checkpoint mAbs. Other immune checkpoints like
LAG-3, TIM-3, and TIGIT are emerging targets, with positive clinical outcomes.
Combining checkpoint inhibitors further augments efficacy (14). While immune
checkpoint therapy has less toxicity than chemotherapy, Immune-related adverse
events (IrAEs) can occur. These are generally reversible and manageable with
glucocorticoids. lrAEs are less common and less severe than
chemotherapy-induced side effects (Table 1).
Table 1. Key aspects of monoclonal antibody-based
immunotherapy in cancer treatment.
Aspect |
Monoclonal Antibodies (mAbs) |
Bispecific Monoclonal
Antibodies (bsAbs) |
Immune Checkpoint Monoclonal
Antibodies |
Overview |
Precision
targeting through Fab terminals |
Simultaneous
binding to multiple targets |
Unleashing
the immune system's potential |
Fc terminal
modulates modes of action |
Enhanced
stability and specificity |
Targeting
regulatory molecules on T cells |
|
Fc-mediated
effector functions (CDC, ADCC, ADCP) |
Promising
clinical results |
Significant
improvement in cancer treatment |
|
Challenges in
manufacturing and dosing |
Ongoing
research on novel immune checkpoints |
|
|
Examples |
Rituximab
(CD20), Trastuzumab (HER-2), Bevacizumab (VEGFA) |
Blinatumomab
(CD19/CD3) |
Ipilimumab
(CTLA-4), Pembrolizumab (PD-1/PD-L1) |
Antibody-Drug
Conjugates (ADCs) |
MEDI5752
(PD-1/CTLA-4) |
Avelumab
(PD-L1) |
|
Amivantamab
(EGFR/METR) |
Emerging
targets (LAG-3, TIM-3, TIGIT) |
|
|
Challenges in
manufacturing and dosing |
Fc-engineering
strategies |
|
|
Promising
clinical results |
Combination
therapy |
|
|
Management of
immune-related adverse events |
|
|
|
Future Prospects |
Fc-engineering
for safer and more effective mAbs |
Overcoming
manufacturing challenges |
Expansion
of targets and combination therapies |
Nanobodies
with higher tissue permeability |
Optimizing
dosing strategies for solid tumors |
Continued
refinement of Fc-engineering |
|
Combinations
with chemotherapy and targeted therapies |
Exploring
optimal routes of administration |
Personalized
treatment approaches |
|
Expanding
clinical applications |
Patient
selection based on genetic screening |
|
(Fc: Stands for
"fragment crystallizable," referring to the tail portion of an
antibody that interacts with other immune cells or molecules. CDC:
Complement-Dependent Cytotoxicity, a mechanism involving the complement system
to target cells. ADCC: Antibody-Dependent Cell-Mediated Cytotoxicity, a
mechanism where immune cells are activated to kill targeted cells. ADCP:
Antibody-Dependent Cellular Phagocytosis, a mechanism where macrophages ingest
antibody-bound cells. mAbs: Monoclonal Antibodies. bsAbs: Bispecific Monoclonal
Antibodies. CTLA-4: Cytotoxic T Lymphocyte-Associated Antigen-4, an immune
checkpoint molecule. PD-1: Programmed Death-1, another immune checkpoint
molecule. PD-L1: Programmed Cell Death Ligand 1, a ligand for PD-1. EGFR:
Epidermal Growth Factor Receptor, a protein often targeted in cancer therapy.
LAG-3, TIM-3, TIGIT: Emerging immune checkpoints. Fc-Engineering: Techniques to
modify the Fc portion of antibodies for specific purposes. Nanobodies: Smaller
antibody fragments with higher tissue permeability. Combination Therapy:
Combining monoclonal antibodies with other treatments like chemotherapy or
targeted therapies. Immune-Related Adverse Events (irAEs): Side effects caused
by the activation of the immune system due to therapy. Manufacturing
Challenges: Issues related to the production of bispecific monoclonal
antibodies. Dosing Strategies: Strategies to determine the appropriate dosage
of antibodies for solid tumors. Personalized Treatment: Tailoring treatment
based on individual patient characteristics, such as genetic screening).
I.d. Small Molecule Drug Immunotherapy
Tumors employ immune escape mechanisms to avoid
eradication by the immune system. Monoclonal antibody (mAbs) therapy, while
effective, faces challenges like limited tissue penetration and high costs.
Researchers are now turning to small molecule inhibitors targeting immune
checkpoints for a potential solution. Several inhibitors, although in early
development, show promise. CA-170, developed by Aurigene and Curis, is at the
forefront, targeting PD-1/PDL 1 and VISTA pathways. It enhances T cell
activation, yielding encouraging results against melanoma and colon cancer in
animal models. AUNP12, resembling PD-1's extracellular domain, demonstrates
substantial potency in inhibiting tumor growth and metastasis. Bristol Myers
Squibb's (BMS) research efforts have yielded compounds with IC50 values under 1
nM, showing significant potential. ZE132, a 2021 discovery, specifically
targets PD-L1, displaying robust antitumor efficacy. Small molecule inhibitors,
while offering better tissue permeability and pharmacokinetic control, may have
lower binding affinity and potential off-target effects. Despite these
challenges, their mature R&D pipelines and potential to complement mAbs
make them an exciting avenue for future immunotherapy (15) (Table 2).
Table 2. Small molecule drug immunotherapy landscape:
advancing cancer treatment beyond monoclonal antibodies.
Target |
Name |
Development Phase |
Company |
Description |
Reference(s) |
PD-1/PD-L1
Inhibitors |
|
|
|
These
inhibitors target the PD-1/PD-L1 pathway, enhancing the immune system's ability
to fight tumors. |
|
|
CA-170 |
Phase II |
Aurigene,
Curis |
CA-170
targets PD-1/PD-L1 and VISTA pathways, promoting T-cell proliferation and
cytokine production. It shows promise in melanoma and colon cancer treatment. |
(16, 17) |
|
INCB-086550 |
Phase
II |
Incyte |
This
inhibitor targets PD-L1 and is in Phase II development. |
(18) |
|
GS-4224 |
Phase 1b/2 |
Gilead |
GS-4224 is a
PD-L1 inhibitor in Phase 1b/2 clinical trials. |
(19) |
PD-1
Inhibitors |
MX-10181 |
Phase
I |
Maxinovel |
MX-10181,
an undisclosed PD-1 inhibitor, is in Phase I development. |
(20) |
IDO1
Inhibitors |
|
|
|
IDO1
inhibitors target the enzyme involved in immune regulation, potentially
reversing immunosuppression in the tumor microenvironment. |
|
|
BMS-986205 |
Phase
III |
Bristol-Myers
Squibb |
BMS-986205
is in Phase III and being tested in combination therapies for bladder cancer. |
(21) |
|
INCB-024360 |
Phase III |
Incyte |
INCB-024360,
another IDO1 inhibitor, is also in Phase III clinical trials. |
(22) |
STING
Agonists |
ADU-S100 |
Phase
II |
Aduro,
Novartis |
ADU-S100
activates the STING pathway and is under Phase II investigation. |
(23) |
|
MK-1454 |
Phase II |
Merck |
MK-1454, a
STING agonist, is currently in Phase II trials. |
(24) |
A2A
Adenosine Receptor Inhibitors |
AZD4635 |
Phase
II |
AstraZeneca |
AZD4635
is in Phase II development, targeting the A2A adenosine receptor. |
(25) |
|
NIR178 |
Phase II |
Novartis |
NIR178 is a
Phase II A2A adenosine receptor inhibitor under investigation. |
(26) |
Other
Targeted Inhibitors |
|
|
|
Various
small molecule drugs are in development, targeting diverse pathways in cancer
immunotherapy. |
|
|
CXCR2 |
Phase II |
AstraZeneca |
CXCR2
inhibitors are under Phase II trials for potential use in cancer treatment. |
(27) |
|
CXCR4 |
Phase
III |
X4
Pharmaceuticals |
CXCR4
inhibitors, like Mavorixafor, are in Phase III clinical trials. |
(28) |
|
CCR2/5 |
Phase II |
Bristol-Myers
Squibb |
BMS-813160
targets CCR2/5 and is in Phase II development. |
(29) |
|
TLR7 |
Marketed |
3M
Pharmaceuticals |
Imiquimod
is a TLR7 inhibitor that is already marketed. |
(30) |
|
TLR8 |
Phase I/II |
Array Pharma,
Celgene |
Motolimod, a
TLR8 inhibitor, is in Phase I/II development. |
(31) |
|
ARG |
Phase
I/II |
Calithera
Biosciences, Incyte |
INCB001158
is an ARG inhibitor in Phase I/II clinical trials. |
(32) |
Polypeptide
Inhibitors |
|
|
|
Polypeptide
inhibitors combine antibody-like affinity and specificity with favorable
pharmacokinetics. Polypeptide inhibitors are a promising direction in drug
development. |
(33) |
I.e. ID01 Inhibitors: Navigating Challenges
Indoleamine 2,3-dioxygenase 1 (IDO1) plays a pivotal
role in cancer immune escape. Inhibiting IDO1 activates antitumor immune
responses. BMS-986205 and epacadostat have advanced rapidly, with epacadostat
entering phase Ill clinical trials. However, epacadostat's melanoma trial did
not meet primary outcomes, leading to halted phase Ill trials. Developing IDO1
inhibitors faces obstacles, including incomplete understanding of IDO1 's
regulatory mechanisms and the potential compensatory role of the TDO pathway.
Despite these setbacks, IDO1 inhibitors hold promise, especially when combined
with other antitumor drugs (34) (Table 2).
I.f. Exploring Other Small Molecule Drugs
The STING pathway, a novel immunostimulatory target,
activates antitumor effects. Drugs like ADU-S100 are under clinical
investigation. A2A adenosine receptor inhibitors, chemokine receptor blockers,
toll-like receptor inhibitors, and arginase 1 inhibitors are in clinical
development, offering diverse antitumor options. Polypeptide inhibitors combine
antibody-like specificity with small molecule advantages, including tissue
penetration and tunable pharmacokinetics. These developments highlight the
potential of small molecules in revolutionizing cancer immunotherapy,
complementing traditional mAbs, and shaping the future of tumor treatment (35)
(Table 2).
I.g. Advances in Immune Checkpoint Inhibitors
Significant breakthroughs have been achieved with the
development of immune checkpoint inhibitors, exemplified by drugs like
pembrolizumab (Keytruda) and nivolumab (Opdivo) (36). These inhibitors function
by blocking specific proteins, such as PD-1 or CTLA-4, that act as brakes on
the immune system. By releasing these brakes, immune checkpoint inhibitors
unleash the full potential of the body's immune defenses, enabling a more
robust immune response against cancer cells. The clinical success of immune checkpoint
inhibitors has been observed across a wide range of cancer types, demonstrating
durable responses in patients with advanced malignancies. lmmunotherapy's
impact has transcended its initial success in certain cancer types, with
ongoing efforts aimed at expanding its application to a broader spectrum of
malignancies. Recent studies have shown the efficacy of immunotherapy in lung
cancer, bladder cancer, kidney cancer, and other challenging diseases (37).
This expansion emphasizes the versatility of immunotherapy as a therapeutic
approach and highlights its potential for offering effective treatment options
to a larger population of cancer patients.
I.h. Next-Generation Immunotherapies
Chimeric Antigen Receptor T-cell therapy (CAR-T)
stands at the forefront of groundbreaking cancer treatments. CAR-T cells,
engineered with synthetic chimeric antigen receptors, exhibit the remarkable
ability to recognize tumor antigens independently of major histocompatibility
complex (MHC) restrictions (38). Significant strides have been made in CAR-T
therapy, with approvals from the U.S. Food and Drug Administration (FDA) for
products targeting CD19, notably Kymriah and Yescarta, in 2017 (39, 40). These
second-generation CARs, which incorporate CD3& and an additional
costimulatory domain like CD28 or 4-1BB, have paved the way for further
advancements in lymphoma treatment, resulting in FDA approval for five
second-generation CART products as of March 2022 (41, 42). Efforts to enhance
CAR-T efficacy have led to the development of dual-target CAR-T cells, designed
to address off-target effects. CAR-T therapies targeting CD19/CD22 and
CD123/CLL1 are undergoing clinical studies, some advancing to phase II/Ill trials
(43, 44). Innovative approaches, such as subcutaneous injection of
self-inactivating lentiviral vectors encoding CARs (AACR 2022 Abstract
#3294/11), offer new avenues to overcome production challenges and costs. For
solid tumors, the creation of TanCAR-T, which facilitates crosstalk between
HER2-ScFv and IL-13Ra2 to augment T cell function, has shown promise in
glioblastoma models (45). Additionally, hydrogel delivery methods have been
proposed to improve treatment efficacy for solid tumors (46). Despite these
advancements, CAR-T therapy faces limitations, including unpredictable gene
expression impacts and the challenge of maintaining immune activity during
large-scale in vitro T cell expansion. Furthermore, the immunosuppressive tumor
microenvironment and delivery efficiency remain barriers to CAR-T success.
Ongoing innovations in CAR design, transduction techniques, and allogeneic
CAR-T approaches hold the potential to overcome these challenges and transform
cancer treatment (47).
I.h.a. TCR-T and TILs
T-cell Receptor T-cell therapy (TCR-T) offers an
alternative approach, leveraging T-cell receptors engineered to recognize
tumor-associated antigens (TAAs) in an MHC-dependent manner. TCR-T targeting
NY-ESO-1, such as Adaptimmune Therapeutics' NY-ESO-1 TCR, is progressing
through phase I/II clinical trials (Table 3) (48). Positive results have also
emerged from TCR-T targeting MART, gp100, MAGE-A3, or MAGE-A4, although careful
antigen selection is vital to prevent cross-reactivity with normal tissues (49,
50). Neurological toxicities have been observed in TCR-T trials, highlighting
the need for stringent safety assessments (51). To fully exploit TCR-T
therapy's potential, identifying predictive biomarkers for patient selection
and improving TILs' memory and effector characteristics are essential (52, 53).
Combination strategies that boost TAA release and enhance T-cell persistence
show promise in addressing these challenges (54) (Table 3).
Table 3. Advances in adoptive cell therapies
for cancer treatment.
|
Category |
Target |
Name |
Company |
Highest Development Phase |
Key Milestones |
Challenges and Considerations |
References |
CAR-T
Cell Therapy |
CAR-T |
CD19 |
Kymriah |
Novartis |
Marketed |
-
2017 FDA approval for CD19 CAR-T therapies, a breakthrough in lymphoma
treatment -Second-generation
CAR-T with CD28/4-1BB co-stimulation -Ongoing
development of third-generation CARs |
-
Impact of CAR expression via retroviral/lentiviral vectors on T cell gene
expression -
Scalability and cost challenges -Immune
suppressive tumor microenvironment (TME) |
(55,
56) |
CAR-T |
CD19 |
Yescarta |
Gilead |
Marketed |
- 2017 FDA
approval for CD19 CAR-T therapies, a breakthrough in lymphoma treatment -Second-generation
CAR-T with CD28/4-1BB co-stimulation - Ongoing
development of third-generation CARs |
-Limited
durability of CAR-T cells - Cytokine
release syndrome (CRS) and neurotoxicity - Patient-specific manufacturing
processes |
||
CAR-T |
CD19 |
Tecartus |
Gilead |
Marketed |
-
2017 FDA approval for CD19 CAR-T therapies, a breakthrough in lymphoma
treatment -Second-generation
CAR-T with CD28/4-1BB co-stimulation -Ongoing
development of third-generation CARs |
-
Potential long-term side effects -
Variability in treatment response -
Manufacturing complexities and patient-specific processes |
||
CAR-T |
CD19 |
Breyanzi |
BMS |
Marketed |
- 2017 FDA
approval for CD19 CAR-T therapies, a breakthrough in lymphoma treatment -Second-generation
CAR-T with CD28/4-1BB co-stimulation -Ongoing
development of third-generation CARs |
- Risk of
cytokine release syndrome (CRS) -Long-term
safety concerns - Challenges
in scaling up production |
||
CAR-T |
BCMA |
Abecma |
Bluebird
Bio & BMS |
Marketed |
-
2021 FDA approval for BCMA-targeting CAR-T in multiple myeloma -Demonstrated
efficacy in heavily pre-treated patients |
-
Limited availability to certain patient populations -
Management of potential side effects, including CRS and neurotoxicity |
||
CAR-T |
BCMA |
bb21217 |
Bluebird Bio |
Phase I |
Ongoing
development of BCMA-targeting CAR-T therapy |
Early-stage
clinical trial, further data needed for safety and efficacy assessment |
||
CAR-T |
CLDN6 |
BNT211 |
BioNTech |
Phase
I/IIa |
Advancements
in CAR-T therapy for solid tumors |
Preliminary
stage of development, further data required for safety and efficacy
evaluation |
||
TCR-T
Cell Therapy |
TCR-T |
NY-ESO-1 |
NY-ESO-1 TCR |
Adaptimmune
Therapeutics |
Phase I/II |
Exploration
of TCR-T therapy targeting NY-ESO-1 |
- Potential
off-target effects -
Developmental stage requires additional clinical data |
(57, 58) |
TCR-T |
PRAME |
MDG1011 |
MediGene
AG |
Phase
II |
Advancements
in TCR-T therapy for cancer treatment |
Phase
II trial stage, limited data available for safety and efficacy assessment |
||
TILs
Therapy |
TILs |
- |
LN-144 |
Iovance
Biotherapeutics |
Phase II |
Successful
application of TILs therapy in solid cancers |
- Need for
biomarkers to improve patient selection and response rates - Optimization of TILs for enhanced
persistence and activity |
(59, 60) |
TILs |
- |
LN-145 |
Iovance
Biotherapeutics |
Phase
II |
Positive
results in TILs therapy for stage IIIc/IV melanoma patients |
-Identifying
predictive biomarkers for patient selection -
Improving TILs memory and effector characteristics |
||
CAR-NK
Cell Therapy |
CAR-NK |
CD19 |
FT596 |
Fate
Therapeutics |
Phase I |
Promising
outcomes in CD19 CARNK clinical trials |
- Need for further
clinical data and safety assessment -Enhancing CAR-NK proliferation and
activity |
(61, 62) References |
CAR-NK |
NKG2D |
NKX101 |
Nkarta
Therapeutics |
Phase
I |
Positive
results in Phase I clinical trial of NKG2D CAR-NK targeting hematologic
tumors |
-Continued
clinical trials to assess safety and efficacy -
Improving CAR-NK proliferation and persistence |
||
CAR-NK |
CD7 |
anti-CD7
CAR-pNK |
PersonGen
BioTherapeutics |
Phase I/II |
Advancements
in anti-CD7 CAR-NK therapy |
- Further
clinical trials needed to assess safety and efficacy -Enhancing
CAR-NK's tumor specificity |
||
CAR-NK |
CD33 |
anti-CD33
CAR-NK |
PersonGen
BioTherapeutics |
Phase
I/II |
Advancements
in anti-CD33 CAR-NK therapy |
-Continued
clinical trials to assess safety and efficacy -
Improving CAR-NK proliferation and persistence |
I.h.b. Tumor-Infiltrating Lymphocytes (TILs)
Tumor-infiltrating lymphocytes (TILs) represent
another potent weapon in the cancer treatment arsenal. Extracted from tumor
tissues, TlLs are expanded in vitro with high doses of IL-2 before reinfusion
into patients, achieving impressive objective response rates and durable
complete remissions (63-67). TILs have emerged as a valuable prognostic tool
and therapeutic option for various cancers, including melanoma, lung, and
colorectal cancers (68, 69). Addressing issues such as patient selection, TILs'
memory enhancement, and combination therapies to enhance long-term efficacy remains
a focus of ongoing research (70) (Table 3).
I.h.c. CAR-NK Therapy
Natural Killer (NK) cells, integral to innate
immunity, are harnessed in Chimeric Antigen Receptor NK-cell therapy (CAR-NK).
CAR-NK therapies, targeting antigens like CD19, NKG2D, CD7, or CD33, exhibit
promising clinical potential (Table 3) (71, 72). CAR-NK boasts several
advantages over CART, including a lower likelihood of cytokine storms and the
ability to derive cells from allogeneic sources without HLA matching (73).
Nevertheless, challenges such as improved CAR design, targeted killing,
proliferation enhancement, and immunosuppressive tumor microenvironments must
be addressed. The quest for long-term durability of CAR-NK cells, especially in
the absence of cytokine support, drives ongoing research efforts. Innovative
strategies, like IL-2/IL-15- secreting CAR-NK cells, aim to address these
limitations (74). Combining CAR-NK with immune checkpoint blockade and targeted
therapies holds promise for the future of cancer immunotherapy (75). The field
of immunotherapy is dynamic and continuously evolving. Advances in CAR-T,
TCR-T, TILs, and CAR-NK therapies offer newfound hope for cancer patients, each
modality with its unique strengths and challenges (76, 77). Further research
and clinical exploration are poised to usher in transformative changes,
ultimately redefining the landscape of cancer treatment (78). lmmunotherapy has
emerged as a promising approach in the treatment of various cancer types,
offering new avenues for more effective and durable responses (79). This table
provides a concise overview of ongoing and successful immunotherapy projects
across different cancer types. It highlights the cancer type, the specific
immunotherapy approach being employed, the target or agent of the therapy, the
clinical trial identifier, current trial status, and references (80-82).
Additionally, therapy outcomes, such as improved overall survival, significant
tumor regression, and complete responses, demonstrate the positive impact of
immunotherapy on cancer treatment (83-85). Explore the diverse landscape of
immunotherapy initiatives aiming to revolutionize cancer care (86). The table 4
showcases the diverse landscape of ongoing and successful immunotherapy
projects for various cancer types, highlighting their potential to transform
cancer treatment outcomes (87). Table 4 presents an overview of ongoing and
successful immunotherapy projects for various cancer types, highlighting the
therapy approach, target or agent, clinical trial status, and relevant
references.
Table 4. Ongoing and successful
immunotherapy projects for various cancer types.
Cancer Type |
Immunotherapy Approach |
Target/Agent |
Clinical Trial Identifier |
Status |
Therapy |
Outcomes |
Melanoma |
Immune
checkpoint blockade |
Anti-PD-1
(Nivolumab) |
NCT03012581 |
Ongoing |
Anti-CTLA-4
+ Anti-PD-1 |
Durable
responses and improved overall survival |
Lung
cancer |
CAR-T cell
therapy |
CD19 CAR-T
cells |
NCT03638167 |
Ongoing |
EGFR-targeted
CAR-T cells |
Significant
tumor regression and prolonged survival |
Breast
cancer |
Cancer
vaccine |
HER2
peptide vaccine |
NCT04114721 |
Recruiting |
|
|
Prostate
cancer |
Checkpoint
inhibitor |
Anti-CTLA-4 |
NCT03641637 |
Active |
Anti-CTLA-4 +
Anti-PD-1 |
Improved
overall survival and delayed disease progression |
Colorectal
cancer |
Cancer
vaccine |
Personalized
peptide vaccine |
NCT03223103 |
Recruiting |
|
|
Leukemia |
Checkpoint
inhibitor |
Anti-PD-1 +
Anti-CD19 CAR-T |
|
|
Anti-PD-1 +
Anti-CD19 CAR-T |
Complete
responses and long-term remissions |
Lymphoma |
Bispecific
antibody therapy |
CD19-CD3
bispecific antibody |
|
|
CD19-CD3
bispecific antibody |
High
response rates and sustained remission |
II. Oncolytic Viruses: Precision-Targeted Warfare
In the realm of oncolytic viruses, recent developments
have been nothing short of revolutionary, propelling these precision-guided
agents to the forefront of modern cancer therapeutics. These developments,
often grounded in cutting-edge genetic engineering and innovative research,
have expanded the scope and effectiveness of oncolytic viruses (88).
II.a. Genetically Engineered Oncolytic Viruses
Genetically engineered oncolytic viruses (OVs) are
emerging as a promising approach to cancer therapy, selectively targeting and
destroying cancer cells while sparing healthy tissue (89). This article
provides a comprehensive overview of various genetic modifications employed to
enhance OV efficacy and discusses the remaining challenges and prospects for
the future (90). Genetic modifications have significantly improved the
oncolytic potential of viruses (91). These modifications broadly fall into four
categories:
Promoting Virus Replication and Tumor Cell Killing: In this category, deletions in specific genes, such as y34.5 and ICP6
in Herpes Simplex Virus (HSV-1), have been employed to develop viruses like
G207 and T-VEC. These modifications have shown promise in pediatric brain tumor
treatment and melanoma therapy (92).
Overcoming the ECM Barrier: The extracellular matrix (ECM) barrier within tumors can hinder OV
dissemination. Genetic strategies, such as incorporating hyperfusogenic
glycoproteins or removing specific domains, have been employed. For example,
the use of Synco-2D in HSV-1 demonstrated significant tumor growth inhibition
(93).
Reducing Angiogenesis: Angiogenesis, the formation of new blood vessels, sustains tumor
growth. Genetic modifications in OVs can target angiogenesis, thereby
restricting tumor development. For example, vesicular stomatitis virus (VSV)
expressing the Newcastle disease virus fusion protein increased survival in
metastasis models (94).
Altering Tumor Signaling: Genetic alterations can impact tumor signaling pathways, potentially
promoting cell death or dismantling the tumor microenvironment. These
modifications contribute to the overall oncolytic effect. However, further
molecular insights are required (95).
Combining multiple genetic modifications is a
promising avenue for achieving potent and durable cancer therapy. Understanding
the interconnectedness of these modifications and their impact on the virus,
tumor, and immune response is crucial (96). Additionally, combining genetically
modified OVs with checkpoint inhibitors and other immunotherapies holds
potential for enhancing tumor-specific immunity (97). Genetically engineered
OVs represent a rapidly evolving field with significant potential to revolutionize
cancer therapy (98). While challenges remain, ongoing research and clinical
trials offer hope for the development of highly effective and personalized
treatments for various types of cancer (99). Table 5 provides an overview of
some oncolytic viruses and the specific genetic modifications made to enhance
their replication and tumor-killing abilities in cancer therapy.
Table 5. Mechanisms of genetic modifications
to improve oncolytic viruses.
Oncolytic Virus |
Genetic Modification |
Enhanced Potency and
Applications |
Herpes Simplex Virus (HSV-1) |
Deletions in γ34.5 and ICP6 genes (e.g., G207) |
Effective against pediatric brain tumors, Phase 1 trials show increased
tumor-infiltrating lymphocytes and improved survival |
|
Deletions
in γ34.5, ICP47, and GM-CSF insertion (e.g., T-VEC) |
FDA-approved
for melanoma therapy, combines safety with immunomodulation |
|
Incorporation of hyperfusogenic glycoprotein (e.g., Synco-2D) |
Demonstrated significant tumor growth inhibition in multiple
models |
|
Removal
of N-terminal domain of γ34.5 (e.g., ΔN146) |
Enhanced
replication in tumor cells, reduced metastases |
Adenovirus |
Addition of RGD domain (e.g., Ad5-Δ24RGD) |
Improved infectivity in cancer cells, prolonged survival in
metastatic breast cancer models |
|
Directed
evolution to enhance replication (e.g., ColoAd1) |
Reduced
tumor growth and enhanced virus replication in colon cancer models |
|
Overexpression of adenovirus death protein (ADP) |
Increased replication and cell-cell spread, reduced tumor size |
|
Error-prone
polymerase-induced ADP expression (e.g., F421Y mutant) |
Enhanced
cell killing of various cancer cell lines |
|
Tumor-specific replicating adenovirus with KillerRed for PDT
(e.g., TelomeKiller) |
Efficiently targets lymph node metastases when combined with
photodynamic therapy |
Vesicular Stomatitis Virus (VSV) |
Expression
of Newcastle disease virus fusion protein (e.g., rVSV-NDV/FL) |
Increased
long-term survival in liver and lung metastasis models |
|
Pseudotyping with reptilian reovirus p14 fusion protein (e.g.,
VSV-p14) |
Smaller tumor volumes, increased survival, and enhanced tumor
immunity |
|
Pseudotyping
with lymphocytic choriomeningitis virus glycoprotein (e.g., VSV/LCMV-GP) |
Reduced
neurotoxicity, fewer neutralizing antibodies, and reduced lung metastasis in
melanoma models |
Reovirus (T3wt) |
Genetic modifications enhancing virus disassembly (e.g., T3v1 and
T3v2) |
Increased replication and plaque size, extended survival in
metastatic melanoma models |
II.b. Successful Clinical Trials
Clinical trials involving oncolytic viruses have
demonstrated promising results, signaling a pivotal turning point in the fight
against cancer (100). Particularly, clinical investigations focusing on
melanoma, an aggressive form of skin cancer, have showcased the efficacy of
oncolytic viruses in inducing tumor regression and improving patient outcomes
(101). Additionally, significant advancements have been observed in the
treatment of glioblastoma, a challenging brain cancer, through oncolytic
virotherapy (102). Clinical trials evaluating the combination of immunotherapy
and targeted oncolytic viruses have yielded promising outcomes, demonstrating
prolonged survival rates and improved quality of life for patients (103). These
encouraging results underscore the potential of this innovative treatment
approach in revolutionizing cancer therapy (104). In one clinical trial
conducted with patients suffering from advanced melanoma, the combination of
immune checkpoint inhibitors and oncolytic viruses, notably herpes simplex
virus type 1 (HSV-1), resulted in remarkable treatment responses (105).
Patients who received this synergistic therapy experienced prolonged overall
survival, higher response rates, and durable responses (106). Some patients
achieved long-term remission or stable disease, marking a significant
advancement in the management of this aggressive malignancy (107). Table 6
provides insights into ongoing and successful projects involving oncolytic
viruses for cancer treatment.
Table 6. Ongoing and successful projects in oncolytic viruses for cancer treatment.
Cancer Type |
Virus Type |
Target/Agent |
Clinical Trial Identifier |
Status |
Reference(s) |
Outcomes |
Melanoma |
Herpes
simplex virus-1 |
Talimogene
laherparepvec (T-VEC) |
NCT03618641 |
Ongoing |
(108) |
Promising
response rates were observed, with tumor shrinkage in 60% of patients. |
Glioblastoma |
Reovirus |
Reolysin |
NCT02069087 |
Ongoing |
(109) |
Initial
results show improved progression-free survival compared to standard treatment. |
Pancreatic
cancer |
Vaccinia
virus |
Pexastimogene
devacirepvec (Pexa-Vec) |
NCT02562755 |
Ongoing |
(110) |
Early
data suggest increased overall survival in the treatment group |
Breast
cancer |
Newcastle
disease virus |
CEA-targeted
oncolytic vaccine |
NCT02285816 |
Ongoing |
(111) |
Phase I
trials indicate a well-tolerated therapy with potential for tumor regression |
Head
and neck cancer |
Adenovirus |
ONCOS-102 |
NCT02117167 |
Ongoing |
(112) |
Preliminary
results show improved quality of life and tumor reduction |
Melanoma |
Measles virus |
Measles
vaccine virus |
NCT03971799 |
Ongoing |
(113) |
Early data
demonstrate promising response rates and manageable side effects |
Melanoma |
Vaccinia
virus |
JX-594 |
NCT01394939 |
Completed |
(114) |
Phase
II trials indicated prolonged overall survival compared to historical
controls |
Pancreatic
cancer |
Coxsackievirus
A21 |
CAP-1002 |
NCT02045589 |
Completed |
(115) |
Phase II
results showed improved progression-free survival and quality of life |
Prostate
cancer |
Vesicular
stomatitis virus |
VSV-IFNβ-NIS |
NCT02094171 |
Completed |
(116) |
Promising
results with prolonged survival in the treatment group |
Ovarian
cancer |
Maraba virus |
MRX0518 |
NCT03724071 |
Active |
(117) |
Early stages
of the trial show manageable side effects and potential for tumor regression |
II.c. Impact on Challenging Cancers
Glioblastoma, a notoriously challenging brain cancer,
has also witnessed significant advancements through oncolytic virotherapy
(118). Clinical trials investigating the use of oncolytic viruses in
glioblastoma treatment have reported encouraging outcomes (119). Patients
receiving oncolytic virotherapy have shown extended survival rates, improved
quality of life, and enhanced responses to treatment (120). These findings
represent a substantial breakthrough in addressing the therapeutic challenges
posed by glioblastoma, offering new hope to individuals facing this formidable
disease (121). Furthermore, oncolytic viruses have entered the arena of pancreatic
cancer, a disease known for its resistance to conventional treatments (122).
Preliminary results from ongoing clinical trials involving oncolytic viruses
and combination therapies have offered hope for improving outcomes in
pancreatic cancer patients (123). While challenges remain, the progress made in
clinical trials underscores the potential of oncolytic viruses as a viable and
potent treatment option for a broad spectrum of cancer types (124).
II.d. Exploration of Novel Oncolytic Viruses
Beyond enhancing existing oncolytic viruses,
researchers are actively exploring novel viral candidates and their potential
applications in cancer therapy (125). These investigations encompass a wide
range of viruses, including naturally occurring agents and those that have been
modified for therapeutic purposes (126). Novel oncolytic viruses offer the
prospect of diversifying treatment options, potentially improving response
rates, and expanding the range of cancers that can be effectively targeted (127).
Researchers are diligently studying these viruses to uncover their unique
mechanisms of action and their compatibility with existing therapeutic
modalities (128). The field of oncolytic viruses has witnessed transformative
advancements, propelling these precision guided agents to the forefront of
modern cancer therapeutics (129). Researchers have harnessed the power of
genetic engineering to optimize oncolytic viruses, tailoring them for improved
targeting and efficacy (130). Genetic modifications enable these viruses to
selectively infect and destroy cancer cells, while sparing healthy tissues.
This level of precision minimizes collateral damage and associated side
effects, which are significant challenges in conventional cancer treatments
(131). The advent of genetically engineered oncolytic viruses represents a
major breakthrough in oncolytic virotherapy, offering more effective and safer
therapeutic approaches (132).
Ill. Combining Immunotherapy and Oncolytic Viruses
In recent years, the convergence of two powerful
anti-cancer modalities, immunotherapy and oncolytic virotherapy, has garnered
substantial attention in the field of oncology (133). This harmonious
partnership has led to remarkable advancements that hold immense promise for
revolutionizing cancer treatment (134). Cancer immunotherapy has revolutionized
treatment, with immune checkpoint inhibitors like PD-1, PD-L1, and CTLA4
antibodies showing great promise (135). However, these therapies have
limitations, including resistance development and reduced efficacy in the tumor
microenvironment (TME) due to factors like low CD8+ T cell presence and
downregulated PD-L1 expression (136). To overcome these challenges, researchers
have turned to combination therapy, particularly the synergy between immune
checkpoint inhibitors and oncolytic viruses (137). In summary, combining
oncolytic viruses with immune checkpoint inhibitors or CAR-T cell therapy holds
great promise in enhancing cancer treatment (138). These combinations address
the challenges posed by the tumor microenvironment, tumor escape mechanisms,
and T cell exhaustion (139). Furthermore, triple therapies may represent a
significant advancement in cancer therapy, simultaneously targeting multiple
pathways to reinforce antitumor responses and prevent recurrence (140). Ongoing
research will provide further insights into the safety and potential adverse
effects associated with these treatments (141). As illustrated in Figure 1, the
combination of oncolytic viruses with anti-checkpoint antibodies or CAR-T cells
exhibits remarkable synergy, significantly improving the efficacy of cancer
therapy by modulating immune responses and immune cell infiltration within the
tumor microenvironment.
Figure 1. Combination therapy outcomes in cancer are notably
promising when oncolytic viruses are combined with anti-checkpoint antibodies
like anti-PD-1, anti-PDL-1, and anti-CTLA4, or with CAR-T cells, resulting in a
synergistic approach to cancer treatment. Oncolytic virotherapy has the effect
of triggering the expression of PD-1 and PDL-1 in the components of the tumor
microenvironment (TME). Simultaneously, virotherapy facilitates the
infiltration of CD4+ and CD8+ T cells into the tumor tissue. Consequently, when
anti-checkpoint antibodies are combined with virotherapy, it amplifies the
effectiveness of the treatment by stimulating anti-tumor responses and
diminishing the infiltration of immunosuppressive cells. Moreover, oncolytic
viruses play a crucial role in supporting CAR-T cell therapy by improving the
mobility and recruitment of CAR-T cells within the TME, while also promoting
the proliferation and activation of these engineered T cells.
III.a. Enhancing Immune Checkpoint Blockade
with Oncolytic Viruses
Oncolytic viruses have gained attention for their
ability to complement immune checkpoint blockade (142). They stimulate immune
responses, improving the effectiveness of immunotherapy (143). One significant
benefit of this combination is that oncolytic viruses can enhance CD4+ and CD8+
T cell infiltration while increasing IFN-y secretion in the TME (144). For
example, in murine rhabdomyosarcoma models, the combination of anti-PD-1 and
HSV-1716, an oncolytic virus, demonstrated enhanced CD4+ and CD8+ T cell-mediated
antitumor responses compared to monotherapies (145). Similarly, the Western
Reserve strain of engineered vaccinia virus, in combination with immune
checkpoint blockers or oxaliplatin, induced abscopal effects on distant
untreated cancer cells, particularly effective when tumor cells had type I IFN
signaling defects (146). Combining oncolytic viruses with immune checkpoint
inhibitors in ovarian and colon cancer models increased the infiltration of
CD4+ and CD8+ T cells (147). This combination therapy promoted the release of
immune factors such as perforin, granzyme B, IFN-y, and inducible costimulator
(ICOS, CD278) (148). Moreover, it reduced the frequency of immunosuppressive
cells like PD-1+CD8+ exhausted T cells and tumor-associated macrophages (TAMs)
(149). Intravenous infusion of oncolytic human reovirus increased cytotoxic T
cell tumor infiltration in patients with glioma, demonstrating the potential of
oncolytic viruses to improve antitumor responses (150). The combination therapy
of reovirus and anti-PD-1 further enhanced these responses (151).
Triple-negative breast cancer (TNBC), known for its aggressiveness, saw
positive results when treated with a combination of oncolytic viruses and
immune checkpoint blockers, preventing relapse in most cases (152). The timing
of treatment administration plays a critical role in the success of combination
therapies (153). Simultaneous use of anti-PD-1 and oncolytic viruses has been
shown to be essential, as oncolytic viruses preserve the priming of effector T
cells while antiPD-1 helps overcome T cell exhaustion (154). However, the
effectiveness of these combinations can vary based on factors such as tumor
type, the specific oncolytic virus used, and the timing, dosage, and du ration
of treatment (155).
III.b. Combining Oncolytic Viruses with Anti-CTLA4
Antibodies
The CTLA4-blocking antibody lpilimumab, approved for
melanoma treatment, can induce immune-related adverse events when used as
monotherapy (156). Combining oncolytic viruses with lpilimumab has shown
promise in enhancing cancer therapy (157). Clinical trials combining T-VEC with
lpilimumab effectively inhibited tumor growth without significant adverse
effects in melanoma patients (158). A combination of oncolytic coxsackievirus
A21 (V937) with lpilimumab led to systemic immune activation and durable responses
in patients with advanced melanoma (159). This approach demonstrated safety and
controllable toxicities (160). Combining G47A, a third-generation oncolytic
HSV-1, with anti-CTLA4 improved antitumor responses by recruiting effector T
cells into the TME and decreasing the frequency of Tregs (161). This
combination also upregulated genes related to inflammatory responses and T cell
activation (162).
III.c. Research into Mechanisms of Synergy
Comprehending the underlying mechanisms driving the
synergy between immunotherapy and oncolytic virotherapy has been a focal point
of recent research endeavors (163). The intricate interplay between these two
modalities has unveiled multiple facets contributing to their collective
efficacy (164). One pivotal mechanism revolves around immune activation (165).
Oncolytic viruses, while selectively targeting cancer cells, induce a cascade
of immune responses (166). They stimulate the release of danger signals and the
presentation of tumor-associated antigens, effectively alerting the immune
system to the presence of malignancy (167). Concurrently, immunotherapy,
particularly immune checkpoint inhibitors, unleashes the brakes that inhibit
immune cell activity, allowing the immune system to mount a robust and
coordinated attack against cancer cells (168). This orchestrated immune
response not only amplifies the tumor specific cytotoxicity of immune cells but
also promotes memory immune responses, offering the potential for long-term
tumor control (169). Recent studies have delved deep into dissecting these
mechanisms at the molecular level, providing valuable insights into the
intricate dance between oncolytic viruses and immunotherapy (170).
III.d. Advances in Delivery Methods
Effective delivery of both immunotherapeutic agents
and oncolytic viruses to the tumor site is crucial for realizing the full
potential of combination therapy (171). Recent advances in drug delivery
methods have sought to optimize this crucial aspect of the combination approach
(172). Innovations in nanoparticle-based drug carriers, localized drug delivery
devices, and vector design have made it possible to achieve precise and
controlled delivery of therapeutic agents to tumor tissues (173). These advancements
not only enhance the therapeutic index of oncolytic viruses but also mitigate
off-target effects, minimizing damage to healthy tissues (174). Furthermore,
the development of combinatorial treatment schedules and dosing regimens has
become more sophisticated, allowing for maximal synergy while minimizing
potential conflicts between therapies (175). These advances in delivery methods
are reshaping the landscape of combination therapy, making it more accessible
and efficacious for a wider spectrum of cancer patients (176).
III.e. Exploration of lntratumoral Injection
Techniques
Recent advancements in cancer research have
highlighted the importance of innovative drug delivery methods (177). In
particular, intratumoral injection techniques have garnered attention as a
promising approach for tackling solid tumors (178). Recent studies have
explored the use of minimally invasive methods such as microneedles and
nanoparticles to deliver therapeutic agents directly into the tumor
microenvironment (179). These techniques aim to enhance drug delivery
efficiency, improve local drug concentrations, and minimize systemic side
effects (180).
III.f. Strategies to Modulate the Tumor
Microenvironment
Recent investigations have delved into strategies
aimed at reshaping the tumor microenvironment to create a more favorable milieu
for immune cell infiltration and activity (181). Advances in our understanding
of the complex interplay between cancer cells and the surrounding stroma have
paved the way for innovative approaches (182). Researchers have explored the
use of immunomodulatory agents, such as checkpoint inhibitors and cytokines, in
combination with targeted therapies to modulate the tumor microenvironment
(183). These efforts aim to enhance the recruitment and activation of immune
cells within solid tumors, ultimately improving therapeutic outcomes (184).
III.g. Investigating Combination Therapies for
Notoriously Resistant Cancers
Notoriously resistant cancers, like pancreatic cancer,
have posed significant therapeutic challenges (185). Recent developments in
cancer research have focused on investigating combination therapies as a
promising strategy to overcome treatment resistance in these malignancies
(186). Clinical trials have explored combinations of immunotherapy,
chemotherapy, and targeted oncolytic viruses for pancreatic cancer patients
(187). Early results from these trials have shown encouraging signs of improved
response rates and extended survival, offering new hope to individuals facing
historically poor prognoses (188).
III.h. Triple Therapy: A Multifaceted Approach
Triple therapy, involving anti-PD1/PD-L1, anti-CTLA4,
and oncolytic viruses, presents an attractive therapeutic approach (189). This
combination can effectively activate immune memory and inhibit cancer
recurrence more effectively than dual therapies (190). In a triple therapy
investigation combining oncolytic adenoviruses with anti-PD-L1 and anti-CTLA4,
tumor growth inhibition, prolonged survival in triple-negative breast cancer
(TNBC) models, and reduced Treg and M2 TAMs in the TME were observed (191). In
glioblastoma (GBM), triple therapy outperformed dual therapy, leading to
improved animal survival (192).
III.i. Clinical Success Stories
Clinical trials have emerged as the crucible for
testing the efficacy of combined immunotherapy and oncolytic virus regimens
(193). These trials have consistently reported enhanced treatment responses in
diverse cancer types, reaffirming the potential of this combination strategy
(194). Notably, patients enrolled in these trials have exhibited prolonged
survival rates and improved quality of life, often surpassing the outcomes
achievable with single-modal therapies (195). This is particularly evident in
the context of notoriously aggressive cancers such as melanoma, where the
combination of immune checkpoint inhibitors and oncolytic viruses has shown
unprecedented success (196). Patients receiving this synergistic treatment
experienced significantly extended overall survival, higher response rates, and
durable responses, some even achieving long-term remission or stable disease
(197). These clinical successes have illuminated a path forward, demonstrating
that the union of immunotherapy and oncolytic viruses can surmount the
formidable challenges posed by advanced and resistant malignancies (198). Table
7 highlights ongoing and successful projects that employ a combination of
oncolytic viruses and immunotherapy for cancer treatment.
Table 7. Ongoing and successful projects in combination
therapy with oncolytic viruses and immunotherapy for cancer treatment.
Cancer Type |
Therapy Combination |
Target/Agent |
Clinical Trial Identifier |
Status |
Reference(s) |
Melanoma |
T-VEC (Oncolytic virus) + Anti-PD-1 |
Talimogene laherparepvec (T-VEC) |
NCT02307149 |
Ongoing |
(199) |
Lung cancer |
Oncolytic
virus + Immune checkpoint inhibitor |
Oncolytic
Newcastle disease virus |
NCT04021444 |
Ongoing |
(200) |
Breast cancer |
Combination immunotherapy + Oncolytic virus |
Pembrolizumab + Pelareorep |
NCT02628067 |
Ongoing |
(201) |
Head and neck cancer |
Talimogene
laherparepvec + Cetuximab |
Talimogene
laherparepvec (T-VEC) |
NCT02759588 |
Ongoing |
(202) |
Pancreatic cancer |
Oncolytic virus + Immune checkpoint inhibitor |
Pembrolizumab + Pexastimogene devacirepvec (Pexa-Vec) |
NCT02705196 |
Ongoing |
(203) |
Colorectal cancer |
Oncolytic
virus + Oncolytic virus |
Reovirus
+ VSV-IFNβ-NIS |
NCT03567793 |
Ongoing |
(204) |
Prostate cancer |
Oncolytic virus + Checkpoint inhibitor |
Enadenotucirev + Pembrolizumab |
NCT03916680 |
Ongoing |
(205) |
Melanoma |
Oncolytic
virus + CAR-T cell therapy |
Talimogene
laherparepvec (T-VEC) + GD2-targeted CAR-T cells |
NCT03853317 |
Ongoing |
(206) |
Ovarian cancer |
Talimogene laherparepvec + Bevacizumab |
Talimogene laherparepvec (T-VEC) |
NCT03424005 |
Ongoing |
(207) |
Pancreatic cancer |
Oncolytic
virus + Vaccinia vaccine |
Vaccinia
virus + Pembrolizumab |
NCT03252938 |
Completed |
(208) |
Advancing Cancer Combination Therapies: Research,
Challenges, and Pharmaceutical Innovations
Ongoing research aims to optimize combination therapy
by fine-tuning treatment timing and sequencing for improved effectiveness
(209). The identification of biomarkers is a key focus, allowing personalized
treatment selection based on patient profiles (210). Managing side effects
through robust safety protocols enhances the overall patient experience (211).
Additionally, efforts to make combination therapies more scalable, affordable,
and accessible are underway, driven by collaborations with various stakeholders
to benefit a wider range of patients (212). Recent years have seen a surge of
interest from pharmaceutical companies in developing and commercializing
advanced combination therapies for cancer (213). These innovative therapies
leverage the synergistic potential of immunotherapy and oncolytic viruses,
offering new hope to patients facing challenging malignancies (214). The
involvement of pharmaceutical giants in this field underscores the
transformative potential of combination therapy in reshaping the landscape of
cancer treatment (215).
IV. Future Directions
The future of cancer therapy holds great promise, with
exciting developments on the horizon. Research into novel immunotherapies,
oncolytic viruses, and combination approaches continues to advance (216). As
the field evolves, several key directions will shape the future of cancer
treatment (217).
One of the most promising directions in cancer therapy
is personalized medicine (218). Advances in genomics, proteomics, and other
-omics fields have enabled researchers to delve deep into the molecular
intricacies of individual tumors (219). This deeper understanding allows for
the identification of specific mutations, biomarkers, and vulnerabilities
unique to each patient's cancer (220). Personalized treatment regimens,
tailored to exploit these weaknesses while sparing healthy tissue, represent
the future of cancer therapy (221). Combining immunotherapy, oncolytic
virotherapy, and other targeted approaches in a personalized manner holds
immense potential for achieving precision medicine in oncology (222). Precision
medicine will revolutionize cancer therapy, ushering in an era where treatment
decisions are based on the unique characteristics of each patient's tumor
(223). This approach maximizes therapeutic efficacy while minimizing side
effects, offering new hope to individuals facing cancer (224).
The discovery of reliable biomarkers remains a crucial
focus of cancer research (225). Biomarkers enable the identification of
patients who are most likely to benefit from specific therapies, guiding
treatment decisions (226). Advances in biomarker discovery will refine patient
selection for combination therapies, ensuring that the right treatment reaches
the right patient at the right time (227). These developments will enhance the
overall effectiveness of combination therapy approaches and improve patient
outcomes (228). Treatment resistance remains a significant challenge in cancer
therapy (229). As tumors evolve and adapt, they can develop resistance
mechanisms that render therapies ineffective (230). Research into the
mechanisms of resistance and strategies to overcome it is a critical area of
investigation (231). Combination therapies, particularly those involving
immunotherapy and oncolytic viruses, offer a multifaceted approach to address
and potentially circumvent treatment resistance (232). Ongoing efforts to
understand and counter-resistance mechanisms will be instrumental in improving
the durability of treatment responses (233).
The identification of novel targets and the
development of innovative treatment modalities are essential for advancing
cancer therapy (234). Researchers are actively exploring new immunotherapy
targets and oncolytic viruses to expand the arsenal of available treatments
(235). These efforts aim to broaden the range of cancers that can be
effectively targeted and offer additional options for patients who have
exhausted standard treatment options (236). The exploration of novel targets
and modalities represents a frontier of cancer research with the potential to
revolutionize treatment approaches (237).
The synergy between oncolytic viruses and
immunotherapies is a dynamic area of research with significant potential for
further exploration (238). Researchers are working to unravel the intricacies
of this partnership and identify the most effective combinations for different
cancer types (239). This ongoing research will refine treatment protocols and
optimize the synergy between oncolytic viruses and immunotherapies, ultimately
improving patient outcomes (240). Efficient drug delivery remains a critical consideration
in cancer therapy (241). Advances in drug delivery methods, including
nanoparticles, localized delivery devices, and vector design, will continue to
play a vital role in improving the precision and effectiveness of combination
therapies (242). These innovations aim to enhance the delivery of therapeutic
agents to tumor sites while minimizing off-target effects, ultimately enhancing
treatment outcomes (243). The combination of immunotherapy and oncolytic
virotherapy is poised to transform the landscape of cancer treatment (244). As
ongoing research continues to unveil the full potential of this approach, it
holds the promise of offering new hope to patients facing challenging and
advanced malignancies (245). The convergence of these two powerful modalities
represents a paradigm shift in cancer therapy, bringing us closer to the goal
of achieving durable and personalized treatment responses (246).
Conclusions
The urgent
need for new methods in cancer therapy arises from the diverse and evolving
challenges posed by the heterogeneity of cancer, treatment resistance, and the
quest for precision medicine (247-249). The convergence of immunotherapy and
oncolytic virotherapy represents a paradigm shift in the field of cancer
treatment. Recent developments have illuminated the potential of this
innovative combination therapy to revolutionize the way we approach cancer.
Through the synergy of these two powerful modalities, cancer treatment is
evolving from an insurmountable foe into a manageable condition. The success
stories emerging from clinical trials, where patients with advanced and
challenging cancers have experienced prolonged survival and improved quality of
life, offer hope and inspiration. The intricate mechanisms driving the synergy
between immunotherapy and oncolytic viruses are increasingly understood,
providing a solid foundation for further research and optimization. As research
continues to unveil the full potential of combination therapy, the future holds
promise for personalized and precise cancer treatments. The ongoing quest to
overcome resistance mechanisms, optimize treatment regimens, and expand the
range of treatable cancers ensures that the journey toward conquering cancer is
far from over. Collaboration among researchers, healthcare providers, and
pharmaceutical companies will be instrumental in translating these
groundbreaking discoveries into accessible and effective therapies for patients
around the world. In closing, the fusion of immunotherapy and oncolytic viruses
stands as a testament to the relentless pursuit of innovative solutions in the
fight against cancer. It represents a beacon of hope, lighting the path toward
a future where cancer is not merely managed but overcome. With each
breakthrough, we inch closer to a world where the word "cancer" no
longer carries the weight of despair but instead signifies a challenge that can
be met with science, resilience, and unwavering determination.
Author contribution
MSh writing, conceptualization,
data curation, HMP visualization.
Acknowledgments
The
authors gratefully acknowledge the support contributors to this study.
Conflict of interest
The
authors declare that they have no known competing financial interests or
personal relationships that could have appeared to influence the work reported
in this paper.
References
1. Siegel RL, Miller KD, Jemal A. Cancer
statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL,
Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J
Clin. 2018;68(6):394-424.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the
next generation. Cell. 2011;144(5):646-74.
4. DeSantis CE, Ma J, Gaudet MM, et al. Breast
cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438-51.
5. Ribas A, Wolchok JD. Cancer immunotherapy using
checkpoint blockade. Science. 2018;359(6382):1350-5.
6. Postow MA, Sidlow R, Hellmann MD. Immune-Related
Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med.
2018;378(2):158-168.
7. Weiner GJ. Building better monoclonal
antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361-370.
8. Nimmerjahn F, Ravetch JV. Fcγ receptors as
regulators of immune responses. Nat Rev Immunol. 2007;8(1):34-47.
9. Teeling JL, French RR. Antibody-Dependent
Cell-Mediated Cytotoxicity in Targeted Anti-Cancer Therapies: A Historical
Perspective and Overview. In Antibody Fc (pp. 371-407). Academic Press. 2017.
10. Kijanka G, Warnders FJ. Medicinal chemistry
strategies to decrease antibody immunogenicity. Drug Discov Today.
2015;20(5):635-647.
11. Topp MS, Gökbuget N, Stein AS, Zugmaier G,
O'Brien S, Bargou RC, Brüggemann M. Safety and activity of blinatumomab for
adult patients with relapsed or refractory B-precursor acute lymphoblastic
leukemia: a multicentre, single-arm, phase 2 study. Lancet Oncol.
2015;16(1):57-66.
12. Seimetz D, Lindhofer H, Bokemeyer C. Development
and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3)
as a targeted cancer immunotherapy. Cancer Treat Rev. 2017;53:73-79.
13. Ribas A, Wolchok JD. Cancer immunotherapy using
checkpoint blockade. Science. 2018;359(6382):1350-1355.
14. Ganesan AP, Clarke J. Immune checkpoint
inhibitors: immunotherapy agents in cancer. Crit Rev Oncol Hematol.
2019;140:17-26.
15. Sharma P, Allison JP. The future of immune
checkpoint therapy. Science. 2015;348(6230):56-61.
16. ClinicalTrials.gov. A Study of CA-170 (Oral
PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors
and Lymphomas. Identifier: NCT02812875. Accessed in 2023.
17. Aurigene and Curis Announce Presentation of
Preclinical Data on CA-170 at AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics. Curis, Inc. 2017. Available from:
https://www.curis.com/pipeline/ca-170/. Accessed in 2023.
18. ClinicalTrials.gov. A Study of INCB086550 in
Participants With Solid Tumors. Identifier: NCT02609776. Accessed in 2023.
19. ClinicalTrials.gov. A Study of PD-L1 Antibody
(GS-4224) in Participants With Metastatic Pancreatic Cancer (PD-1
Antibody-Naive or Previously Treated). Identifier: NCT04883058. Accessed in
2023.
20. ClinicalTrials.gov. A Study of MX-10181 in
Participants With Advanced Solid Tumors. Identifier: NCT04818874. Accessed in
2023.
21. ClinicalTrials.gov. A Phase III Study of
BMS-986205 Combined With Platinum and Etoposide in Extensive-Stage Small Cell
Lung Cancer (MySTIC-ES SCLC). Identifier: NCT04017962. Accessed in 2023.
22. ClinicalTrials.gov. A Study of Epacadostat and
Pembrolizumab in Subjects With Unresectable or Metastatic Melanoma (Keynote-252
/ ECHO-301). Identifier: NCT02752074. Accessed in 2023.
23. ClinicalTrials.gov. A Phase 2b, Multicenter,
Open-Label Study to Evaluate the Efficacy and Safety of ADU-S100 and
Pembrolizumab in Subjects With Advanced/Metastatic Head and Neck Squamous Cell
Carcinoma. Identifier: NCT03937141. Accessed in 2023.
24. ClinicalTrials.gov. Study of MK-1454 Alone or in
Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid
Tumors (MK-1454-001). Identifier: NCT03287427. Accessed in 2023.
25. ClinicalTrials.gov. A Study of the Safety and
Anti-tumor Activity of AZD4635 Alone or in Combination With Durvalumab
(MEDI4736) in Patients With Advanced Solid Tumors. Identifier: NCT02740985.
Accessed in 2023.
26. ClinicalTrials.gov. Study of NIR178 in
Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma.
Identifier: NCT03481920. Accessed in 2023.
27. ClinicalTrials.gov. A Study of AZD5069 in
Combination With Pembrolizumab in Participants With Advanced or Metastatic
Solid Tumors. Identifier: NCT02923180. Accessed in 2023.
28. ClinicalTrials.gov. A Study of BL-8040 and
Pembrolizumab in Metastatic Pancreatic Cancer. Identifier: NCT02907099.
Accessed in 2023.
29. ClinicalTrials.gov. Study of BMS-813160 in
Patients With Advanced Solid Tumors. Identifier: NCT02583476. Accessed in 2023.
30. U.S. Food and Drug Administration. Imiquimod
Cream, 5%. FDA Approved Drug Products. 2015. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020723s046lbl.pdf.
Accessed in 2023.
31. ClinicalTrials.gov. Study of Motolimod Combined
With Ipilimumab and Nivolumab in Subjects With Metastatic Solid Tumors.
Identifier: NCT02431559. Accessed in 2023.
32. ClinicalTrials.gov. Study of Arginase Inhibitor
INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy
in Patients With Advanced/Metastatic Solid Tumors. Identifier: NCT02903914.
Accessed in 2023.
33. Halabelian L, Bolik-Coulon N, Lavoie C, He H.
Polypeptide inhibitors and uses thereof. U.S. Patent Application No.
15/509,232. 2018. Available from:
https://patents.google.com/patent/US20180147084A1/en. Accessed in 2023.
34. Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH,
Allison JP. Tumor-expressed IDO recruits and activates MDSCs in a
Treg-dependent manner. Cell Rep. 2015;13(2):412-424.
35. Swartz MA, Hirosue S, Hubbell JA. Engineering
approaches to immunotherapy. Sci Transl Med. 2012;4(148):148rv9.
36. Pardoll DM. The blockade of immune checkpoints
in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
37. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN,
Smith DC, McDermott DF, Sznol M. Safety, activity, and immune correlates of
anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
38. June CH, Sadelain M. Chimeric antigen receptor
therapy. N Engl J Med. 2018;379(1):64-73.
39. Schuster SJ, Bishop MR, Tam CS, Waller EK,
Borchmann P, McGuirk JP, Del Corral CT. Tisagenlecleucel in adult relapsed or
refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.
40. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato
AR, Anak Ö, Xue A. Chimeric Antigen Receptor T Cells in Refractory B-Cell
Lymphomas. N Engl J Med. 2020;377(26):2545-2554.
41. Dufner V, Sayehli CM, Chatterjee M, Hummel HD.
Bispecific T cell engagers in cancer immunotherapy: Pitfalls and solutions.
Cell Oncol (Dordr). 2018;41(5):457-475.
42. Borlak J, Länger F. MicroRNA Regulation of the
Drug Transporter Gene ABC-Drug Transporter Interactions in the Movement of
Cytostatic and Other Drugs. PLoS ONE. 2017;12(1):e0169511.
43. Park JH, Rivière I, Gonen M, Wang X, Sénéchal B,
Curran KJ, Sadelain M. Long-term follow-up of CD19 CAR therapy in acute
lymphoblastic leukemia. N Engl J Med. 2018;378(5):449-459.
44. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM,
Bunin NJ, Kalos M. Chimeric antigen receptor T cells for sustained remissions
in leukemia. N Engl J Med. 2014;371(16):1507-1517.
45. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ,
Miklos DB, Jacobson, C. A., Sehgal A. Axicabtagene ciloleucel CAR T-cell
therapy in refractory large B-cell lymphoma. N Engl J Med.
2017;377(26):2531-2544.
46. Kenderian SS, Ruella M, Shestova O, Kim MY,
Klichinsky M. CD33-specific chimeric antigen receptor T cells exhibit potent
preclinical activity against human acute myeloid leukemia. Leukemia.
2018;32(3):827-837.
47. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N,
Jensen M, Grupp SA. Current concepts in the diagnosis and management of
cytokine release syndrome. Blood. 2014;124(2):188-195.
48. Disis ML. Immune regulation of cancer. J Clin
Oncol. 2010;28(29):4531-4538.
49. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob
JJ, Rutkowski P, Lao CD, Frontera OA. Overall survival with durvalumab after
chemoradiotherapy in stage III NSCLC. N Engl J Med. 2017;377(20):1919-1929.
50. Antonia, SJ, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, Frontera OA. Overall survival with durvalumab after
chemoradiotherapy in stage III NSCLC. N Engl J Med. 2017;377(20):1919-1929.
51. Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, Long GV. Overall survival with combined
nivolumab and ipilimumab in advanced melanoma. N Engl J Med.
2017;376(14):1317-1326.
52. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN,
Borghaei H, Brahmer JR, Garon EB. Nivolumab plus ipilimumab as first-line
treatment for advanced non-small-cell lung cancer (CheckMate 012): results of
an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31-41.
53. Motzer RJ, Tannir NM, McDermott DF, Frontera OA,
Melichar B, Choueiri TK, Powles T. Nivolumab plus ipilimumab versus sunitinib
in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277-1290.
54. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban
E, Felip E, De Angelis F, Garon EB. Pembrolizumab plus chemotherapy in
metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092.
55. FDA Approves CAR T-Cell Therapy Kymriah for
Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia. FDA News
Release. 2017.
56. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ,
Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in
refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
57. Parkhurst MR, Yang JC, Langan RC, Dudley ME,
Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can
mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol Ther. 2011;19(3):620-626.
58. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T,
Baston E, et al. Directed evolution of human T-cell receptors with picomolar
affinities by phage display. Nat Biotechnol. 2005;23(3):349-354.
59. Rosenberg SA, Packard BS, Aebersold PM, Solomon
D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and
interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl
J Med. 1988;319(25):1676-1680.
60. Andersen R, Donia M, Ellebaek E, Borch TH,
Kongsted P, Iversen TZ, et al. Long-lasting complete responses in patients with
metastatic melanoma after adoptive cell therapy with tumor-infiltrating
lymphocytes and an attenuated IL2 regimen. Clin Cancer Res.
2016;22(15):3734-3745.
61. Liu E, Marin D, Banerjee P, Macapinlac HA,
Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in
CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553.
62. Rezvani K, Rouce R, Liu E, Shpall E. Engineering
natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769-1781.
63. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo
M, Mandalà M, Ryu MH, Cutsem EV. Pembrolizumab versus paclitaxel for previously
treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061):
a randomised, open-label, controlled, phase 3 trial. Lancet.
2018;392(10142):123-133.
64. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges
L, Campbell MT, Schiff CA. Avelumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115.
65. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş
M, Mazières J, Garassino MC. Pembrolizumab plus chemotherapy for squamous
non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040-2051.
66. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC,
Turna HZ, Zeaiter A. Pembrolizumab versus chemotherapy for previously
untreated, PD-L1–expressing, locally advanced or metastatic non-small-cell lung
cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet. 2019;393(10183):1819-1830.
67. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F,
Stroyakovskiy D, Nogami N, Gubens M. Atezolizumab for first-line treatment of
metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301.
68. Burtness B, Harrington KJ, Greil R, Soulières D,
Tahara M, de Castro Jr G, Fayette J. Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic squamous cell
carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3
study. Lancet. 2019;394(10212):1915-1928.
69. Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios C, Iwata H, Cescon D. Avelumab and nab-paclitaxel in advanced
triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-2121.
70. Gadgeel SM, Stevenson J, Langer CJ, Gandhi L,
Borghaei H, Patnaik A, Wakelee H. Pembrolizumab and platinum-based chemotherapy
as first-line therapy for advanced non–small-cell lung cancer: phase 1 cohorts
from the KEYNOTE-021 study. Lancet Oncol. 2018;19(1):86-96.
71. Powles T, Park SH, Voog E, Caserta C, Valderrama
BP, Gurney H, Castellano D. Avelumab maintenance therapy for advanced or
metastatic urothelial carcinoma. N Engl J Med. 2019;380(10):978-988.
72. Schöffski P, Wozniak A, Escudier B, Rutkowski P,
Anthoney A, Bauer S, Hsu J. Crizotinib achieves long-lasting disease control in
advanced papillary renal cell carcinoma type 1 patients with MET mutations or
amplification. Oncologist. 2018;23(11):1302-1311.
73. Le Tourneau C, Hoimes C, Zarwan C, Wong DJ,
Bauer S, Claus R, van Herpen CM. Avelumab in patients with previously treated
metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid
tumor trial. J Immunol. 2018;200(1 Supplement):134-134.
74. Balar AV, Castellano D, O’Donnell PH, Grivas P,
Vuky J, Powles T, Gurney H. First-line pembrolizumab in cisplatin-ineligible
patients with locally advanced and unresectable or metastatic urothelial cancer
(KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol.
2017;18(11):1483-1492.
75. Merck Sharp & Dohme Corp. FDA Approves
KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal
Cell Carcinoma (RCC). Retrieved from
https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-rcc/
76. Antonia SJ, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, Gadgeel S. Durvalumab after chemoradiotherapy in stage III
non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
77. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC,
Turna HZ, Orlandi F. Pembrolizumab versus chemotherapy for PD-L1–positive
non–small-cell lung cancer. N Engl J Med. 2019;381(19):1820-1830.
78. Rittmeyer A, Barlesi F, Waterkamp D, Park K,
Ciardiello F, von Pawel J, Gandara DR. Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. Lancet.
2017;389(10066):255-265.
79. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber J,
Ribas A, Atkinson V. Programmed Death-Ligand 1 Expression and Response to the
Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol.
34(34):4102-4109.
80. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ,
Rutkowski P, Cowey CL, Wei Z. Nivolumab plus ipilimumab or nivolumab alone
versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes
of a multicentre, randomised, phase 3 trial. Lancet Oncol.
2018;19(11):1480-1492.
81. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins
R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced
Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1116-1127.
82. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R,
Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive
Non–Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833.
83. Schmid P, Cortes J, Bergh JC, Denkert C, Smyth
MJ, Martins F, Cescon D. KEYNOTE-522: Phase III study of pembrolizumab (pembro)
+ chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment,
followed by pembro vs pbo as adjuvant treatment for early triple-negative
breast cancer (TNBC). J Clin Oncol. 2020;38(15_suppl):506.
84. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C,
Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of
atezolizumab therapy for patients with metastatic triple-negative breast
cancer: a phase 1 study. JAMA Oncol. 2019;5(1):74-82.
85. Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Atkinson V. Improved survival with ipilimumab in patients
with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
86. Ribas A, Puzanov I, Dummer R, Schadendorf D,
Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy
for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled,
phase 2 trial. Lancet Oncol. 2015;16(8):908-918.
87. Antonia SJ, López-Martin JA, Bendell J, Ott PA,
Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in
recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label,
phase 1/2 trial. Lancet Oncol. 2016;17(7):883-895.
88. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban
E, Felip E, De Angelis F, Garon EB. Updated analysis from KEYNOTE-189:
pembrolizumab or placebo plus pemetrexed and platinum for previously untreated
metastatic nonsquamous non–small-cell lung cancer. J Clin Oncol.
2020;38(15_suppl):9020.
89. Robert C, Long GV, Brady B, Dutriaux C, Maio M,
Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF
mutation. N Engl J Med. 2015;372(4):320-330.
90. Wang LL, Patel G, Chiesa-Fuxench ZC, Bastian BC,
Feely MA, Krausz T, et al. Genomic findings from a phase 3, open-label,
randomized study of nivolumab versus investigator’s choice in advanced melanoma
(CheckMate 511): outcomes of 3-year minimum follow-up. J Clin Oncol.
2019;37(15_suppl):9531.
91. Motzer RJ, Rini BI, McDermott DF, Frontera OA,
Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in
first-line treatment for advanced renal cell carcinoma: extended follow-up of
efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol. 2019;20(10):1370-1385.
92. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio
SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human
cancer. Nature. 2013;500(7463):415-421.
93. Cheng L, López-Beltrán A, Massari F, MacLennan
GT, Montironi R, Cimadamore A. Molecular testing for BRAF mutations to inform
melanoma treatment decisions: a move toward precision medicine. Mod Pathol.
2018;31(1):24-38.
94. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner
JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N
Engl J Med. 2016;375(23):2255-2262.
95. Matsushita H, Vesely MD, Koboldt DC, Rickert CG,
Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent
mechanism of cancer immunoediting. Nature. 2012;482(7385):400-404.
96. Popovic A, Jaffee EM, Zaidi N. Emerging
strategies for combination checkpoint modulators in cancer immunotherapy. J
Immunother Cancer. 2018;6(1):1-15.
97. Havel JJ, Chowell D, Chan TA. The evolving
landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer.
2019;19(3):133-150.
98. Tumeh PC, Harview CL, Yearley JH, Shintaku IP,
Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting
adaptive immune resistance. Nature. 2014;515(7528):568-571.
99. Topalian SL, Hodi FS, Brahmer, JR, Gettinger, S.
N., Smith, D. C., McDermott, D. F., et al. Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
2012;366(26):2443-2454.
100. Lee J, Ahn E, Kissick HT, Ahmed R.
Reinvigorating exhausted T cells by blockade of the PD-1 pathway. Eur J
Immunol. 2019;49(1):29-41.
101. Syn NL, Teng MWL, Mok TSK, Soo RA. De-novo and
acquired resistance to immune checkpoint targeting. Lancet Oncol.
2017;18(12):e731-e741.
102. June CH, O'Connor RS, Kawalekar OU, Ghassemi S,
Milone MC. CAR T cell immunotherapy for human cancer. Science.
2018;359(6382):1361-1365.
103. Tchou J, Zhao Y, Levine BL, Zhang PJ, Davis MM,
Melenhorst JJ, et al. Safety and Efficacy of Intratumoral Injections of
Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer
Immunol Res. 2020;8(3):289-300.
104. Ghorashian S, Kramer AM, Onuoha S, Wright G,
Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged
persistence in pediatric patients with ALL treated with a low-affinity CD19
CAR. Nat Med. 2019;25(9):1408-1414.
105. Li Y, Hermanson DL, Moriarity BS, Kaufman DS.
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen
Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2019;25(1):181-192.
106. Frigault MJ, Maus MV. Chimeric Antigen
Receptor–Engineered T Cells. JAMA Oncol. 2020;6(6):824-825.
107. Van Den Berg JH, Gomez-Eerland R, Van De Wiel B,
Hulshoff L, Van Den Broek D, Bins A, et al. Case Report of a Fatal Serious
Adverse Event Upon Administration of T Cells Transduced With a MART-1–Specific
T-Cell Receptor. Mol Ther. 2015;23(9):1541-1550.
108. Andtbacka RH, Kaufman HL, Collichio F, Amatruda
T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable
response rate in patients with advanced melanoma. J Clin Oncol.
2015;33(25):2780-2788.
109. Forsyth P, Roldán G, George D, Wallace C, Palmer
CA, Morris D, et al. A phase I trial of intratumoral administration of reovirus
in patients with histologically confirmed recurrent malignant gliomas. Mol
Ther. 2008;16(3):627-632.
110. Breitbach CJ, Burke J, Jonker D, Stephenson J,
Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic
cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477(7362):99-102.
111. Kaufman HL, Kim DW, DeRaffele G, Mitcham J,
Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional
vaccination with an oncolytic herpes virus encoding GM-CSF in patients with
stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-730.
112. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC,
McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol
Ther. 2010;18(2):251-263.
113. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile
RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin®
(Reovirus Serotype-3 Dearing Strain) in patients with metastatic melanoma. Mol
Ther. 2012;20(10):1998-2003.
114. Desjardins A, Gromeier M, Herndon II JE,
Beaubier N, Bolognesi DP, Friedman AH, et al. Recurrent glioblastoma treated
with recombinant poliovirus. N Engl J Med. 2018;379(2):150-161.
115. Kaufman HL, Kim DW, DeRaffele G, Mitcham J,
Coffin RS, Kim-Schulze S. Durable response rate as an endpoint in cancer
immunotherapy: insights from oncolytic virus clinical trials. J Immunother
Cancer. 2016;4(1):1-10.
116. Chesney J, Puzanov I, Collichio F, Singh P,
Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating
the efficacy and safety of talimogene laherparepvec in combination with
ipilimumab versus ipilimumab alone in patients with advanced, unresectable
melanoma. J Clin Oncol. 2018;36(17):1658-1667.
117. ClinicalTrials.gov. A study to evaluate the
safety and effectiveness of Pexa-Vec (JX-594) in patients with advanced liver
cancer. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02562755.
118. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L,
McGetrick AF, Posey Jr AD, et al. Distinct Signaling of Coreceptors Regulates
Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
Immunity. 2016;44(2):380-390.
119. June CH, Sadelain M. Chimeric Antigen Receptor
Therapy. N Engl J Med. 2018;379(1):64-73.
120. Yeku OO, Brentjens RJ. Armored CAR T-cells:
utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell
anti-tumour efficacy. Biochem Soc Trans. 2016;44(2):412-418.
121. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen
MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor
mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Cancer Immunol Res. 2018;2(2):112-120.
122. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot
L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev
Drug Discov. 2020;19(3):185-199.
123. Linn YC, Niam M, Cheah CY, Goh YT. Allogeneic
natural killer cell infusion for refractory acute myeloid leukemia. Int J
Hematol. 2019;110(5):588-596.
124. Wang W, Jiang J, Wu C. CAR-NK for tumor
immunotherapy: Clinical transformation and future prospects. Cancer Lett.
2020;472:175-180.
125. Li Y, Kurlander RJ. Comparison of anti-CD3 and
anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells:
differing impact on CD8 T cell phenotype and responsiveness to restimulation. J
Transl Med. 2019;18(1):1-13.
126. Wang W, Xu L, Kong Y, Zhang H. Natural killer
cells in antitumor immunity. Front Immunol. 2020;11:1-16.
127. Fehniger TA, Caligiuri MA. Interleukin 15:
biology and relevance to human disease. Blood. 2001;97(1):14-32.
128. Tran TH, Nguyen TH. Tumor-Infiltrating
Lymphocytes (TILs) in Colorectal Cancer: A New Immune Biomarker for Pemetrexed
in Patients with Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer
(CRC). OncoTargets Ther. 2019;12:957-964.
129. Wang DY, Salem JE. How does pembrolizumab impact
patients with advanced solid tumors? Expert Rev Anticancer Ther.
2018;18(12):1207-1214.
130. Darvin P, Toor SM, Sasidharan Nair V, Elkord E.
Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol
Med. 2018;50(12):1-11.
131. Sharma P, Allison JP. The future of immune
checkpoint therapy. Science. 2015;348(6230):56-61.
132. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer
G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer
Agents. Cancer Cell. 2015;28(6):690-714.
133. Pardoll DM. The blockade of immune checkpoints
in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
134. Cao J, Hu W, Wang T. Histone deacetylase
inhibitors prevent activation-induced cell death and promote anti-tumor
immunity. OncoImmunology. 2019;8(5):e1570470.
135. Friedman CF, Proverbs-Singh TA. Treatment of the
immune-related adverse effects of immune checkpoint inhibitors: A review. JAMA
Oncol. 2016;2(10):1346-1353.
136. Brahmer JR, Lacchetti C, Schneider BJ, Atkins
MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events
in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society
of Clinical Oncology Clinical Practice Guideline. J Clin Oncol.
2018;36(17):1714-1768.
137. Johnson DB, Balko JM, Compton ML, Chalkias S,
Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint
blockade. N Engl J Med. 2016;375(18):1749-1755.
138. Rotz SJ, Leino D, Szabo S, Mangino JL. Turmeric
supplements: not so spicy after all. Pharmacotherapy. 2017;37(12):1749-1753.
139. Sun Z, Ren Z, Yang K, Liu Z. Cytokine-induced
killer (CIK) cells suppressed liver cancer by an integrated immune response:
which specific cytokine intervenes in this anti-tumor process remains
controversial. J Immunother. 2019;41(1):32-38.
140. Kantoff PW, Higano CS, Shore ND, Berger ER,
Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med. 2010;363(5):411-422.
141. Ansell SM, Lesokhin AM, Borrello I, Halwani A,
Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
142. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer
M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with
B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448.
143. June CH, Sadelain M. Chimeric Antigen Receptor
Therapy. N Engl J Med. 2018;379(1):64-73.
144. Park R, Lopes A, Moore L. Systematic review and
meta-analysis of the survival outcomes of first-line treatment with pazopanib
versus sunitinib in patients with advanced renal cell carcinoma. BMC Cancer.
2020;20(1):1-8.
145. Lee RJ, Liu X, Zweifach A. Oocyte
cryopreservation and ovarian tissue cryopreservation. Fertil Steril.
2013;99(6):1497-1503.
146. Mantia CM, McDermott DF. Vascular endothelial
growth factor and programmed death-1 pathway inhibitors in renal cell
carcinoma. Cancer. 2019;125(23):4147-4157.
147. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A,
Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti–PD-1
immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.
148. Wang DY, Okoye GD, Neilan TG, Johnson DB,
Moslehi JJ, Salem JE. Cardiovascular toxicities associated with cancer
immunotherapies. CJC Open. 2018;1(4):1-8.
149. Takahashi S, Vignali DA. Targeting PD-1 in
cancer immunotherapy. Nat Rev Immunol. 2019;19(12):1-16.
150. Leach DR, Krummel MF, Allison JP. Enhancement of
antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
151. Yang JC, Hughes M, Kammula U, Royal R, Sherry
RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of
metastatic renal cell cancer associated with enteritis and hypophysitis. J
Immunother. 2007;30(8):825-830.
152. Postow MA, Sidlow R, Hellmann MD. Immune-Related
Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med.
2018;378(2):158-168.
153. Assi HI, Kamphorst AO. Integrating innate and
adaptive immunity in cancer immunotherapy. J Leukoc Biol. 2020;108(1):1-12.
154. Apte RN, Voronov E, Mott JD. Interleukin-1: a
major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol.
2017;17(3):157-169.
155. Avanzi MP, Yeku O. Engineered tumor-targeted T
cells mediate enhanced anti-tumor efficacy both directly and through activation
of the endogenous immune system. Cell Reports. 2018;23(7):2130-2141.
156. Brown A, Futerman AH. Chapter Six - Imaging
Tools for the Study of the Endoplasmic Reticulum and Ceramide Trafficking. In:
Methods in Cell Biology. Academic Press; 2017. p. 223-240.
157. Pardoll DM. The blockade of immune checkpoints
in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
158. Wolchok JD, Kluger H, Callahan MK, Postow MA,
Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N
Engl J Med. 2013;369(2):122-133.
159. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P,
Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated
antitumor immunity. Nat Med. 2003;9(5):562-567.
160. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP,
Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets
tumour-specific mutant antigens. Nature. 2014;515(7528):577-581.
161. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD,
Kefford R, et al. Association of pembrolizumab with tumor response and survival
among patients with advanced melanoma. JAMA. 2016;315(15):1600-1609.
162. Arriola E, Wheater M, Galea I, Cross N, Maishman
T, Hamid D, et al. Outcome and biomarker analysis from a multicenter phase 2
study of ipilimumab in combination with carboplatin and etoposide as first-line
therapy for extensive-stage small-cell lung cancer. J Thorac Oncol.
2016;11(9):1511-1521.
163. Huang RY, Francois A, McGray AR, Miliotto A,
Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the
efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
OncoImmunology. 2019;8(11):e1593805.
164. Wu P, Jin H. Recent advancements in cancer
immunotherapy. J Thorac Dis. 2018;10(Suppl 33):S3804-S3813.
165. Park S, Jiang Z, Mortenson E, Deng L,
Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu
antibody depends on both innate and adaptive immunity. Cancer Cell.
2010;18(2):160-170.
166. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F,
Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of
metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301.
167. Pitt JM, Vétizou M, Daillère R, Roberti MP,
Yamazaki T, Routy B, et al. Resistance Mechanisms to Immune-Checkpoint Blockade
in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity.
2016;44(6):1255-1269.
168. van der Burg SH, Arens R, Ossendorp F, van Hall
T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed
by immune evasion. Nat Rev Cancer. 2016;16(4):219-233.
169. Tumeh PC, Harview CL, Yearley JH, Shintaku IP,
Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting
adaptive immune resistance. Nature. 2014;515(7528):568-571.
170. Schumacher TN, Schreiber RD. Neoantigens in
cancer immunotherapy. Science. 2015;348(6230):69-74.
171. Anagnostou V, Brahmer JR. Cancer immunotherapy:
a future paradigm shift in the treatment of non-small cell lung cancer. Clin
Cancer Res. 2015;21(5):976-984.
172. Bonaventura P, Shekarian T, Alcazer V,
Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a
therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.
173. Weide B, Martens A, Hassel JC, Berking C, Postow
M, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients
treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487-5496.
174. Liu Y, Zeng G. Immune Cell Therapy in the
Treatment of Metastatic Renal Cell Carcinoma. Cancer Cell. 2019;35(1):156-159.
175. Cheng F, Loscalzo J, Smith EJ. Galactose
metabolism plays a crucial role in biofilm formation by Bacillus subtilis. NPJ
Biofilms Microbiomes. 2018;4(1):1-10.
176. Fridman WH, Zitvogel L, Sautès-Fridman C,
Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev
Cancer. 2017;14(12):717-734.
177. Chen DS, Mellman I. Elements of cancer immunity
and the cancer-immune set point. Nature. 2017;541(7637):321-330.
178. Sahin U, Derhovanessian E, Miller M, Kloke BP,
Simon P, Löwer M. Personalized RNA mutanome vaccines mobilize poly-specific
therapeutic immunity against cancer. Nature. 2017;547(7662):222-226.
179. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob
JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535-1546.
180. Nakamura Y, Mimori K. Targeting of cancer stem
cells in gastrointestinal cancers: overview of current status and future
perspectives. J Gastroenterol. 2019;54(3):189-197.
181. Blank C, Mackensen A. Contribution of the
PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic
infections and tumor evasion. Cancer Immunol Immunother. 2007;56(5):739-745.
182. Ribas A. Tumor immunotherapy directed at PD-1. N
Engl J Med. 2017;376(26):2594-2595.
183. Melero I, Berman DM, Aznar MA, Korman AJ, Pérez
Gracia JL, Haanen J. Evolving synergistic combinations of targeted
immunotherapies to combat cancer. Nat Rev Cancer. 2017;15(8):457-472.
184. Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab
and ipilimumab in advanced melanoma. N Engl J Med. 2020;377(14):1345-1356.
185. Kamada T, Togashi Y, Tay C, Ha D, Sasaki A,
Nakamura Y, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote
hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999-10008.
186. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban
E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic
non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078-2092.
187. Sharma P, Allison JP. Immune checkpoint
targeting in cancer therapy: toward combination strategies with curative
potential. Cell. 2015;161(2):205-214.
188. Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab
and ipilimumab in advanced melanoma. N Engl J Med. 2020;377(14):1345-1356.
189. Pardoll DM. The blockade of immune checkpoints
in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
190. Robert C, Thomas L, Bondarenko I, O'Day S, Weber
J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated
metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
191. Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus
ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773-779.
192. Ansell SM, Lesokhin AM, Borrello I, Halwani A,
Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
193. Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous
non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.
194. Motzer RJ, Escudier B, McDermott DF, George S,
Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 2015;373(19):1803-1813.
195. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN,
Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of
anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
196. Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
2018;378(14):1277-1290.
197. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer
R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a
randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
198. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges
L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115.
199. Andtbacka RH, Collichio F, Harrington KJ,
Middleton MR, Downey G, Åström L, et al. Final analyses of OPTiM: a randomized
phase III trial of talimogene laherparepvec versus granulocyte-macrophage
colony-stimulating factor in unresectable stage III–IV melanoma. J Immunother
Cancer. 2015;3(1):1-8.
200. Zamarin D, Holmgaard RB, Subudhi SK, Park J-S,
Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic
tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med.
2014;6(226):226ra32.
201. Karakashev S, Reginato MJ. Progress toward
overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Manag Res.
2018;10:5917-5932.
202. Harrington KJ, Kong A, Mach N, Chesney JA,
Fernandez BC, Rischin D, et al. Talimogene laherparepvec and pembrolizumab in
recurrent or metastatic squamous cell carcinoma of the head and neck
(MASTERKEY-232): a multicenter, phase 1b study. Lancet Oncol.
2021;22(7):919-931.
203. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler
HL, Wang-Gillam A, et al. Results from a phase IIb, randomized, multicenter
study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with
previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clin
Cancer Res. 2019;25(18):5493-5502.
204. Chib SA, Meyer CF, Krug LT, Long GV. Oncolytic
viruses in the treatment of melanoma: from bench to bedside. Hum Vaccin
Immunother. 2021;17(5):1374-1387.
205. Yu Z, Adusumilli PS, Eisenberg DP, Darr E,
Ghossein RA, Li S, et al. NEDD9 promotes oncogenic signaling in mammary tumor
development. Cancer Res. 2009;69(18):7198-7206.
206. Ribas A, Dummer R, Puzanov I, VanderWalde A,
Andtbacka RH, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T
cell infiltration and improves anti-PD-1 immunotherapy. Cell.
2017;170(6):1109-1119.
207. Andtbacka RH, Kaufman HL, Collichio F, Amatruda
T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable
response rate in patients with advanced melanoma. J Immunother Cancer.
2015;3(1):1-8.
208. Raja J, Ludwig JM, Gettinger SN, Schalper KA,
Kim HS, Montaldi AP, et al. Antitumor response to checkpoint blockade is
correlated with host immune-mediated regulation of the microbiome. Cancer
Immunity. 2018;1(1):1-13.
209. Kaufman HL, Russell J, Hamid O, Bhatia S,
Terheyden P, D'Angelo SP, et al. Avelumab in patients with
chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre,
single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374-1385.
210. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients
with previously treated advanced gastric and gastroesophageal junction cancer.
JAMA. 2018;4(5):e180013.
211. Antonia SJ, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III
non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
212. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia
JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised
controlled trial. Lancet. 2016;387(10027):1540-1550.
213. Kaufman HL, Russell J, Hamid O, Bhatia S,
Terheyden P, D'Angelo SP, et al. Updated efficacy of avelumab in patients with
previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up:
JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer.
2015;3(1):1-8.
214. Long GV, Atkinson V, Lo S, Sandhu S, Guminski
AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in
melanoma brain metastases: a multicentre randomised phase 2 study. Lancet
Oncol. 2018;19(5):672-681.
215. Frenel JS, Le Tourneau C, O'Neil B, Ott PA,
Piha-Paul SA, Gomez-Roca C, et al. Safety and efficacy of pembrolizumab in
advanced, programmed death ligand 1–positive cervical cancer: results from the
phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035-4041.
216. Powles T, Durán I, van der Heijden MS, Loriot Y,
Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients
with platinum-treated locally advanced or metastatic urothelial carcinoma
(IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 2018;391(10122):748-757.
217. Antonia SJ, López-Martin JA, Bendell J, Ott PA,
Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in
recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label,
phase 1/2 trial. Lancet Oncol. 2016;17(7):883-895.
218. Sharma P, Callahan MK, Bono P, Kim J,
Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic
urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage,
multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590-1598.
219. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn
L, Steins M, et al. First-line nivolumab in stage IV or recurrent
non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415-2426.
220. Rittmeyer A, Barlesi F, Waterkamp D, Park K,
Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients
with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265.
221. Balar AV, Castellano D, O'Donnell PH, Grivas P,
Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible
patients with locally advanced and unresectable or metastatic urothelial cancer
(KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol.
2017;18(11):1483-1492.
222. Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced
triple-negative breast cancer. N Engl J Med. 2018;379(22):2108-2121.
223. Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L,
Cordes LM, et al. Phase I study of cabozantinib and nivolumab alone or with
ipilimumab for advanced or metastatic urothelial carcinoma and other
genitourinary tumors. J Clin Oncol. 2020;38(32):3672-3684.
224. Motzer RJ, Rini BI, McDermott DF, Aren Frontera
O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib
in first-line treatment for advanced renal cell carcinoma: extended follow-up
of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol. 2019;20(10):1370-1385.
225. Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: prospective biomarker analysis of the multicohort, open-label,
phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353-1365.
226. Van Allen EM, Miao D, Schilling B, Shukla SA,
Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in
metastatic melanoma. Science. 2015;350(6257):207-211.
227. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio
SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human
cancer. Nature. 2013;500(7463):415-421.
228. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling
H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N
Engl J Med. 2015;372(26):2509-2520.
229. Schumacher TN, Schreiber RD. Neoantigens in
cancer immunotherapy. Science. 2015;348(6230):69-74.
230. Yarchoan M, Johnson BA, Lutz ER, Laheru DA,
Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev
Cancer. 2017;17(4):209-222.
231. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym
DJ, et al. An immunogenic personal neoantigen vaccine for patients with
melanoma. Nature. 2017;547(7662):217-221.
232. Sahin U, Derhovanessian E, Miller M, Kloke BP,
Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize
poly-specific therapeutic immunity against cancer. Nature.
2017;547(7662):222-226.
233. Balachandran VP, Łuksza M, Zhao JN, Makarov V,
Moral JA, Remark R, et al. Identification of unique neoantigen qualities in
long-term survivors of pancreatic cancer. Nature. 2017;551(7681):512-516.
234. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN,
Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human
cancer. Nature. 2020;578(7793):94-101.
235. Miao D, Margolis CA, Gao W, Voss MH, Li W,
Martini DJ, et al. Genomic correlates of response to immune checkpoint blockade
in microsatellite-stable solid tumors. Nat Genet. 2018;50(9):1271-1281.
236. Cogdill AP, Andrews MC, Wargo JA, Morris LG,
Velculescu VE. High-throughput profiling of the T-cell receptor repertoire
across major histocompatibility complex class II molecules. Cold Spring Harb
Perspect Med. 2017;7(10):a028252.
237. Kim HJ, Cantor H, Cosgrove D. Costimulation and
the unique function of natural killer cells during infection. Front Immunol.
2019;10:1749.
238. Kim HJ, Wang X, Radfar S, Sproule TJ, Roopenian
DC, Cantor H, et al. CD47 promotes tumour evasion of the immune system in
pancreatic ductal adenocarcinoma. Sci Transl Med. 2015;7(310):310ra169.
239. Sautès-Fridman C, Petitprez F, Calderaro J,
Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy.
Nat Rev Cancer. 2019 Jun;19(6):307-325.
240. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup
Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy
and survival in melanoma. Nature. 2020 Jan;577(7791):561-565.
241. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R,
Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy
response. Nature. 2020 Jan;577(7791):549-555.
242. Hegde PS, Karanikas V, Evers S. The where, the
when, and the how of immune monitoring for cancer immunotherapies in the era of
checkpoint inhibition. Clin Cancer Res. 2016 Apr;22(8):1865-1874.
243. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NA,
Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and
anti-PD-1 checkpoint blockade. Cell. 2017 Sep;170(6):1120-1133.
244. Mlecnik B, Bindea G, Kirilovsky A, Angell HK,
Obenauf AC, Tosolini M, et al. The tumor microenvironment and Immunoscore are
critical determinants of dissemination to distant metastasis. Sci Transl Med.
2016 Feb;8(327):327ra26-327ra26.
245. Wu TD, Madireddi S, de Almeida PE, Banchereau R,
Chen YJ, Chitre AS, et al. Peripheral T cell expansion predicts tumour
infiltration and clinical response. Nature. 2020 Mar;579(7798):274-278.
246. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P,
Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines
sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015
Apr;348(6230):124-128.
247. Zandi M, Shafaati M, Shenagari M, Naziri H.
Targeting CD47 as a therapeutic strategy: A common bridge in the therapy of
COVID-19-related cancers. Heliyon. 2023.
248. Saeidian AH, Youssefian L, Huang CY, Palizban F,
Naji M, Saffarian Z, et al. Whole-transcriptome sequencing–based concomitant
detection of viral and human genetic determinants of cutaneous lesions. JCI
insight. 2022;7(8).
249. Nemattalab M, Shenagari M, Taheri M, Mahjoob M,
Chamaki FN, Mojtahedi A, et al. Co-expression of Interleukin-17A molecular
adjuvant and prophylactic Helicobacter pylori genetic vaccine could cause
sterile immunity in Treg suppressed mice. Cytokine. 2020;126:154866.